Objective: To investigate the prognostic value of interleukin-11 receptor α chain in patients with early-stage clear-cell renal cell carcinoma. Interleukin-11 receptor α chain, a member of the gp130-dependent receptors, exerts pleiotropic oncogenic activities by promoting proliferation, angiogenesis and metastasis in many cancers. Methods: We retrospectively enrolled 293 patients (130 in the training cohort and 163 in the validation cohort) with early-stage (TNM Stage I + II) clear-cell renal cell carcinoma undergoing nephrectomy at a single institution. Clinicopathologic features, recurrence-free survival and overall survival were recorded. Interleukin-11 receptor α chain intensities were assessed by immunohistochemistry in tumor tissues. Kaplan-Meier method was applied to compare survival curves between groups. Cox regression models were used to analyze the impact of prognostic factors on recurrence-free survival and overall survival. The concordance index was calculated to assess predictive accuracy. Results: In both training and validation cohorts, high interleukin-11 receptor α chain expression was associated with early recurrence (P = 0.004 and P = 0.015, respectively) and poor survival (P < 0.001 and P = 0.019, respectively) of patients with early-stage clear-cell renal cell carcinoma. Multivariate analyses confirmed that interleukin-11 receptor α chain expression was an independent prognostic factor for recurrence-free survival (P = 0.004) and overall survival (P = 0.001). The predictive accuracy of the Leibovich prognostic score was improved when interleukin-11 receptor α chain expression was incorporated. Notably, the improvement in prediction mainly took place in patients with low-risk disease defined by the Leibovich score. Conclusion: High Interleukin-11 receptor α chain expression is an independent predictor of poor clinical outcome in patients with early-stage clear-cell renal cell carcinoma, and the prognostic value is more prominent in those with low-risk disease.
Introduction
Renal cell carcinoma (RCC), which accounts for 2-3% of all adult malignant neoplasms, is the most lethal urologic cancer. Worldwide, there are ∼209 000 new cases and 102 000 deaths per year (1) . RCC can be cured surgically if detected at early stages. Nevertheless, ∼30% of patients undergoing curative-intended nephrectomy for localized RCC will experience local recurrence or distant metastasis, usually leading to incurable disease. The worldwide incidence rates of RCC have slightly increased within the last three decades (2) . However, thanks to the widespread use of abdominal imaging techniques, the proportion of small, organ-confined tumors with 'low-risk' of cancerspecific death has significantly increased (3) . Related to this, there is a parallel need to develop reliable and inexpensive tests that help recognize the patients with low-risk tumor who will ultimately progress and succumb to their disease.
Inflammatory responses play critical roles in tumor development and progression (4) . Cytokines are now recognized as important mediators linking the inflammatory tumor microenvironment and cancer cell growth, and are therefore potential therapeutic targets and prognostic factors (5) . The interleukin (IL)-6 family of cytokines is defined by the shared use of the gp130 receptor β-subunit and considered as one of the most important cytokine families during tumorigenesis and metastasis (6) . IL-11, a member of the IL-6 cytokine family, recognized for its role in stimulating platelet production and regulating polarization of T cells and macrophages (7) . These effects are mediated by a multimeric complex comprising the ligandbinding IL-11 receptor α-subunit (IL-11R) and the ubiquitously expressed gp130 β-subunit, which together, trigger intracellular signaling and engagement of STAT3 (8) . In turn, activated STAT3 promotes cell survival and proliferation as well as immune responses associated with inflammatory diseases and tumor progression. The action of IL-11 is primarily determined by the expression of the IL-11R, magnitude and kinetic of its induction and biological availability of the ligand (9) .
In this study, we assessed the expression of IL-11R by immunohistochemistry in patients with early-stage clear-cell RCC (ccRCC) and its association with clinicopathologic characteristics and patient outcome. We further evaluated the prognostic significance of IL-11R and its ability to improve the predictive accuracy of well-established prognostic models such as the Leibovich score (10).
Patients and methods

Patients
A total of 293 patients diagnosed with early-stage (TNM Stage I + II) ccRCC at Zhongshan Hospital (Shanghai, China) were retrospectively included in the study. We enrolled a training cohort of 130 consecutive patients undergoing radical or partial nephrectomy between January 2003 and December 2004. For validation, we also enrolled 163 consecutive patients who experienced surgery in 2008. This study was approved by the hospital's ethics committee and informed consent was obtained from each patient. For each patient, the following clinicopathologic information was collected: age, gender, tumor size, TNM stage, Fuhrman grade, presence of histologic tumor necrosis and ECOG-PS. Patients were staged using radiographic reports and postoperative pathological data, and were reassigned according to 2010 AJCC TNM classification. Patients with late stage (TNM Stage III + IV) tumors were considered to have metastatic disease and were excluded from this study. The Leibovich score was applied to the patients, resulting in three risk groups (low-, intermediate-and high-risk).
After surgery, patients were evaluated with physical examination, laboratory studies, chest imaging and abdominal ultrasound or CT scans every 6 months for the first 2 years and annually thereafter. Survival status was updated in March 2014. Median follow-up period was 107 months (range, 12-120 months) in the training cohort and 67 months (range, 13-74 months) in the validation cohort. Recurrencefree survival (RFS) was measured from the date of surgery to the date of recurrence or death from ccRCC, whichever came first. Overall survival (OS) was calculated from the date of surgery to death from all causes.
Tissue microarray (TMA) and immunohistochemistry TMA was created from the formalin-fixed, paraffin-embedded tissue blocks of the patients. All samples were reviewed histologically by hematoxylin and eosin (HE) staining, and representative areas were marked on the paraffin blocks away from necrotic and hemorrhagic materials. Duplicate 1.0 mm tissue cores from two different areas were used to construct the TMAs. Sections from the TMA blocks were cut at 4 μm.
TMA sections were deparaffinized in xylene and hydrated to distilled water. After the endogenous peroxidase was inhibited by 3% H 2 O 2 for 30 min, the sections were heated in a pressure cooker for 5 min in unmasking solution (0.01 M sodium citrate buffer, pH = 6) and then incubated with 10% normal goat serum for 30 min. Primary antibody against human IL-11R (1:100; Abcam, Cambridge, MA, USA) was applied overnight in a moist chamber at 4°C. After the primary antibody was washed off, EnVision Detection System (Dako) was used according to the manufacturer's instructions. A semiquantitative immunohistochemistry score on a scale of 0-300 was calculated for each sample by multiplying the staining intensity (0, no staining; 1, weak; 2, moderate; and 3, strong) and the percentage of tumor cells (0-100%) at each intensity level. The immunostaining was evaluated by two pathologists (L.C. and Q.F.) without the knowledge of patient outcome. The specificity of the anti-IL-11R antibody was confirmed by Western blot using RCC cell lines. Tissue samples processed similarly, except for the omission of the primary antibody, were used as negative controls in immunohistochemistry.
Statistical analyses
The expression of IL-11R was dichotomized into low and high according to the median value of the semiquantitative immunohistochemistry score. Correlations between immunohistochemical variables and clinicopathologic characteristics were analyzed with χ 2 and t tests.
Kaplan-Meier method with log-rank test was applied to compare survival curves. All statistical tests were two sided and performed at a significance level of 0.05. Cox regression models were used to analyze the impact of prognostic factors on RFS and OS. The predictive accuracy of various Cox regression models was quantified by Harrell's concordance index (C-index), which ranges from 0.5 (no predictive power) to 1 ( perfect prediction). Data were analyzed using SPSS 21.0 and MedCalc 12.7.0. (Fig. 1) . The median immunohistochemistry scores for IL-11R were 118 (range, 11-279) and 108 (range, in the training and validation cohorts, respectively. The data showed that IL-11R expression had no statistically significant correlations with age, gender, tumor size, pathologic T stage, Fuhrman grade, tumor necrosis or performance status in both cohorts (Table 2) .
Results
Patient characteristics and associations with IL-11R expression
High expression of IL-11R is associated with poor clinical outcome
Kaplan-Meier survival analyses indicated that high expression of IL-11R is associated with an increased risk of recurrence (P = 0.004 in the training cohort and P = 0.015 in the validation cohort, Fig. 2A and B) and reduced survival (P < 0.001 in the training cohort and P = 0.019 in the validation cohort, Fig. 2C and D) . Since the data from the validation cohort were consistent with that from the training cohort, the two cohorts were merged for further statistical analyses. To investigate whether the aforementioned finding was dependent on tumor stage, TNM Stage I and Stage II subgroups were analyzed separately (Fig. 3) . In the subgroup with TNM Stage I, patients with high IL-11R expression had a poorer RFS [hazard ratio (HR), 4.032; 95% confidence interval (CI), 2.018-8.056; P < 0.001] and OS (HR, 7.603; 95% CI, 2.915-19.833; P < 0.001) than these with low IL-11R expression patients (Fig. 3A and C) . However, in TNM Stage II subgroup, IL-11R expression failed to stratify both RFS and OS (Fig. 3B  and D) . The unfavorable prognostic value of IL-11R was confined to patients with Stage I tumors. In contrast, this association was not observed in patients with Stage II disease. We next evaluated the independent prognostic value of IL-11R expression using Cox regression model. Multivariate analyses showed that, together with Fuhrman grade and tumor necrosis, IL-11R expression is an independent prognostic factor for RFS (HR 2.271; 95% CI 1.296-3.979; P = 0.004; Table 3 ) and OS (HR 3.172; 95% CI 1.577-6.381; P = 0.001; Table 3 ) in patients with early-stage ccRCC after surgery.
Extension of established prognostic models with IL-11R expression
The Leibovich score, which incorporates pathologic T stage, N stage, tumor size, Fuhrman grade and tumor necrosis, was originally developed to predict metastases after radical nephrectomy in patients with localized ccRCC (10). As noted above, high IL-11R expression was associated with a higher risk of recurrence in early-stage ccRCC patients, especially those with Stage I disease. Therefore, we sought to investigate whether incorporation of IL-11R expression into the Leibovich score would improve its predictive accuracy by calculating the C-index. For RFS, the C-index of the original Leibovich score was 0.683, and improved to 0.743 when IL-11R expression was added. Similarly, for OS, the C-index of the original Leibovich score was 0.667, and increased to 0.748 when IL-11R expression was supplemented. Furthermore, a subgroup analysis by Leibovich risk groups showed that the improvement of prognostic stratification was more evident in low-risk patients. In the subgroup with Leibovich lowrisk, patients with high IL-11R expression had a poorer RFS (HR, 3.473; 95% CI, 1.380-8.743; P = 0.005) and OS (HR, 5.431; 95% CI, 1.746-16.894; P = 0.001) than those with low IL-11R expression ( Fig. 4A and C) . In contrast, IL-11R expression had limited ability to stratify patients already predicted to be at combined intermediate-and high-risk of recurrence or survival based on the Leibovich score ( Fig. 4B and D) .
Discussion
In the present study, we demonstrated that high expression of IL-11R is an independent predictor of adverse prognosis in patients with earlystage ccRCC. Furthermore, the incorporation of IL-11R expression into the Leibovich prognostic model would improve its ability to predict recurrences after nephrectomy. Particularly, we found that this improvement in prediction mainly took place in patients classified as low-risk by the Leibovich score. That is, even among this population of low-risk patients where metastases are rare, IL-11R expression could help to identify patients who are more likely to experience postoperative disease progression. Therefore, we recommend using IL-11R staining to better arrange post-operative management. For instance, ccRCC patients with high IL-11R expression may need to undergo adjuvant therapy and a closer follow-up after surgery, although they are low-risk patients according to conventional clinicopathologic features. Turmorigenesis is a multistep process driven by the accumulation of genetic alterations in cancer initiating cells. However, equally important to tumor initiation and progression are the contributions of the inflammatory tumor microenvironment, where cancer cells conscript and corrupt normal, non-mutated stromal cells for their support (11) . Studies utilizing knockout mice have begun to reveal the complex interplay between the neoplastic and stromal cells and have highlighted pivotal roles for inflammatory cytokines. The IL-6 family of cytokines, especially IL-6 and IL-11, drives many of the cancer hallmarks through downstream activation of the gp130/STAT3 signaling pathway (12) . Previous studies suggested that IL-6 is elevated in many cancers, including ovarian (13) (14) (15) , pancreatic (16) and endometrial cancers (17, 18) . In particular, antibodies that neutralize IL-6 or block IL-6R are in clinical trials for ovarian, prostate and kidney cancers (19, 20) . IL-11 is also increased in several cancers, including pancreatic (21), intestine (22) and endometrial cancers (8, 23) . A recent study by Putoczki et al. (12) demonstrated that IL-11 has a more prominent role compared with IL-6 during the progression of colon and gastric cancers. Accordingly, pharmacologic inhibition of IL-11 signaling alleviated STAT3 activation, suppressed tumor cell proliferation and reduced the invasive capacity and growth of tumors. In addition, our current study indicated the role of IL-11R/gp130/STAT3 in tumor progression and potential therapeutic opportunities for RCC. A previous investigation revealed that IL-11R can be selectively targeted to treat primary and metastatic osteosarcoma (24) . Putoczki et al. (12) found that IL-11 signaling can serve as a potential therapeutic target for the treatment of gastrointestinal cancers. Therefore, it is worthwhile to explore inhibition of IL-11R or neutralization of IL-11 as a new adjuvant therapy for RCC.
In recent years, several genetic alterations and components of the inflammatory tumor microenvironment have been identified as novel prognostic biomarkers for RCC patients. Kapur et al. demonstrated that the presence of PBRM1 mutations confer a favorable prognosis, while mutations of BAP1 confer a poor prognosis. The small proportion of patients whose tumors exhibited both BAP1 and PBRM1 mutations had the worst survival of all (25) . A study by Jensen et al. (26) suggested that the presence of intratumoral neutrophils, assessed by CD66b immunostaining, was an independent prognostic factor for dismal prognosis in patients with localized RCC. Data from our study revealed that identification of intratumoral macrophage polarization using CD11c and CD206 immunostaining can predict outcomes for surgically treated RCC patients (27) . Furthermore, Tran et al. (28) reported that cytokine and angiogenic factor profiling has not only prognostic value in patients with metastatic RCC, but also predicts response to pazopanib treatment. Taken together, these biomarkers could help improve the management of RCC in terms of patient stratification, selecting patients for additional treatment and customizing post-surgical surveillance.
Due to the widespread use of abdominal imaging techniques, the proportion of small, organ-confined kidney tumors has significantly increased (29) . However, the natural history of RCC is complex and is influenced by factors other than pathologic stage (30) . It is therefore clinically useful to identify and validate biomarkers of aggressive disease. Thus, we chose to focus on early-stage patients in this study. However, there are several limitations of the current study that warrant further discussion. First, we demonstrated that high IL-11R expression was associated with adverse prognosis in early-stage ccRCC patients. This association was restricted to patients with Stage I diseases, but not observed in those with Stage II diseases. This might be due to limited cases with Stage II disease. We would like to validate our findings in a larger and independent cohort in the future. Second, although two tissue cores from the same tumor allowed the immunohistochemical data to be verified, substantial intratumoral heterogeneity of RCC may influence the findings of this study (31) . Third, experimental studies are needed to explain the biological mechanisms involved in this association.
In conclusion, we demonstrated that high IL-11R expression in ccRCC tissues is associated with a greater risk of recurrence and reduced survival in patients with early-stage ccRCC. In particular, this association is more prominent in patients with low-risk disease.
